title: Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments.
abstract: OBJECTIVE
  Even with the current most effective treatment regimens for Helicobacter pylori infection, a considerable number of patients will be resistant to eradication. The aim of the present study was to evaluate the H. pylori eradication rate in patients resistant to standard therapies when treated with a triple therapy of pantoprazole, rifabutin and amoxicillin.
  
  
  METHODS
  Ninety-two consecutive patients diagnosed with H. pylori infection resistant to two previous treatment regimens were treated with pantoprazole, rifabutin and amoxicillin for 10 days. The persistence or eradication of H. pylori was determined by a 13C-urea breath test performed 4 weeks after the treatment.
  
  
  RESULTS
  Per protocol eradication was achieved in 62.2% of patients and the intention-to-treat eradication was 60.8%. Only two patients were excluded for adverse events related to the treatment.
  
  
  CONCLUSIONS
  The eradication rate is acceptable as a third-line therapy, particularly in centers with high cure rate for first line therapy. Another important value of this study is the good tolerance for the treatment observed in our patients. It is possible that rifabutin-based triple therapy may be of use in hospital centers that do not have disposable culture and susceptibility methods against H. pylori.
authors.affiliation: Digestive Unit, Hospital General Mancha-Centro, Alcázar de San Juan, Spain. psgc@mixmail.com
authors.forename: Pedro
authors.initials: P
authors.lastname: González Carro
authors.forename: Francisco
authors.initials: F
authors.lastname: Pérez Roldán
authors.forename: Aurora
authors.initials: A
authors.lastname: De Pedro Esteban
authors.forename: Maria L
authors.initials: ML
authors.lastname: Legaz Huidobro
authors.forename: Susana
authors.initials: S
authors.lastname: Soto Fernández
authors.forename: Oscar
authors.initials: O
authors.lastname: Roncero Garcia Escribano
authors.forename: Jose M
authors.initials: JM
authors.lastname: Esteban López-Jamar
authors.forename: Carmen
authors.initials: C
authors.lastname: Pedraza Martin
authors.forename: Francisco
authors.initials: F
authors.lastname: Ruíz Carrillo
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077402:Pantoprazole; D017828:Rifabutin / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D017828:Rifabutin; D000658:Amoxicillin; D000077402:Pantoprazole